干扰素基因刺激剂
刺
免疫原性
先天免疫系统
交叉展示
抗原
鸟苷
免疫系统
癌症研究
获得性免疫系统
抗原呈递
生物
细胞生物学
免疫学
T细胞
生物化学
工程类
航空航天工程
作者
Baojin Peng,Zitong Zheng,Jing‐Jie Ye,Xian‐Zheng Zhang
出处
期刊:Nano Letters
[American Chemical Society]
日期:2022-03-07
卷期号:22 (6): 2217-2227
被引量:21
标识
DOI:10.1021/acs.nanolett.1c03996
摘要
Agonists of stimulators of interferon genes (STING) are a promising class of immunotherapeutics that trigger potent innate immunity. However, the therapeutic efficacy of conventional STING agonists, such as 2',3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP), is severely restricted to poor cytosolic delivery and lacks the capacity to promote the recognition of tumor-specific antigens. Here, we tackle these challenges through a nanovaccine platform based on Fenton-reactive and STING-activating nanoparticles, synergistically contributing to the generation of tumor-cell-derived apoptotic bodies (ABs). ABs loaded with exogenous cGAMP are readily phagocytosed by antigen-presenting cells (APCs), as a Trojan horse for rendering tumor cells with high immunogenicity instead of a noninflammatory response. This leads to enhanced STING activation and an improved tumor-specific antigen presentation ability, boosting the adaptive immunity in collaboration with innate immune. The strategy of exploiting a metal-based nanovaccine platform possesses great potential to be clinically translated into a trinitarian system of diagnosis, treatment, and prognosis.
科研通智能强力驱动
Strongly Powered by AbleSci AI